Deutsche Märkte geschlossen

Ipsen S.A. (IPN.PA)

Paris - Paris Verzögerter Preis. Währung in EUR
Zur Watchlist hinzufügen
110,30+1,10 (+1,01%)
Börsenschluss: 05:35PM CET

Ipsen S.A.

65, quai Georges Gorse
Boulogne-Billancourt 92100
France
33 1 58 33 50 00
https://www.ipsen.com

Sektor(en)Healthcare
BrancheDrug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter5.325

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. David LoewMD, CEO & Director2,22MN/A1967
Mr. Aymeric Le ChatelierExecutive VP & CFO731,25kN/A1969
Dr. Aidan Murphy Ph.D.Executive VP and Head of Technical OperationsN/AN/A1966
Mr. Craig MarksVice-President of Investor RelationsN/AN/AN/A
Mr. Francois GarnierExecutive VP of Legal Affairs, General Counsel & Chief Business Ethics OfficerN/AN/A1962
Ms. Gwenan WhiteExecutive VP and Head of Communications, Public Affairs & SustainabilityN/AN/AN/A
Mr. Regis MulotExecutive VP & Chief Human Resources OfficerN/AN/A1966
Ms. Dominique BeryHead of Nordics & BalticsN/AN/A1971
Mr. Bartosz Bednarz D.D.S.Executive VP and Head of Global Product & Portfolio StrategyN/AN/AN/A
Mr. Philippe Lopes-Fernandes CBOExecutive VP & Chief Business OfficerN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.

Corporate Governance

Ipsen S.A.s ISS Governance QualityScore, Stand 1. März 2024, lautet 7. Die grundlegenden Scores sind Audit: 8, Vorstand: 7, Shareholderrechte: 7, Kompensation: 6.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.